Dilemmas and Breakthroughs in the Treatment of Benign Prostatic Hyperplasia in China

Benign prostatic hyperplasia (BPH) is a common urologic disease in elderly men, which seriously affects patients' quality of life. Current treatments mainly include medication and surgery, but both have their own limitations. In recent years, Prostatic Urethral Dilation (PUD), as a new non-resectable mechanical dilatation technique, has gradually become a hot spot for research and clinical application. This article summarizes the current status of BPH treatment in China, the existing dilemmas, and focuses on the technical features and advantages of PUD technology and the latest product, a Ultra-Minimally Invasive Prostate Dilation Catheter (Longevity Bar), with particular attention to its breakthrough in preserving prostate function and reducing postoperative complications, as well as its advantages for high-risk patients based on the innovation of the thermoplastic polyurethane (TPU) material and the precise positioning technology of the double balloon. The clinical appropriateness of the TPU material innovation and double balloon precise positioning technology for the elderly and high-risk patient groups, with a view to providing new treatment ideas for the clinic.